Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title EVarQuit: Extended pre-quit varenicline to assist in quitting smoking
Description Varenicline (Chantix®) is the best quit smoking medication available, but even with varenicline more than half of people return to smoking within 6 months. The main purpose of this clinical research study is to definitively determine whether extended pre-quit varenicline makes it easier to quit and stay quit.

Participants will be in this research study for approximately 6 months, with active treatment for the first four months and a follow-up visit at 6 months

The research will be conducted at the University at Buffalo South Campus, Diefendorf Hall.

If you're interested in this study, please contact the study coordinator listed below.
Objective We aim to improve smoking cessation rates obtained with varenicline, the best quit smoking agent available, by a simple but theory-based manipulation: increasing the duration of pre-quit varenicline treatment from 1 to 4 weeks.

Keywords: Smoking, smoking cessation, addiction
Principal Investigator HAWK, LARRY
Age Group Adult
Drugs Involved
Clinical Trials.gov
Status Not Open
Key Eligibility Ages 18-70
Smoking at least 10 cigarettes per day for the last 6 months
Moderately motivated to quit smoking
Disease Group Other; Substance Abuse/Addictions
Treatment Varenicline (Chantix)
Contact JENNIFER ADAMS
716-829-5967
jpadams@buffalo.edu